BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1185 related articles for article (PubMed ID: 27572267)

  • 1. Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity.
    Li CW; Lim SO; Xia W; Lee HH; Chan LC; Kuo CW; Khoo KH; Chang SS; Cha JH; Kim T; Hsu JL; Wu Y; Hsu JM; Yamaguchi H; Ding Q; Wang Y; Yao J; Lee CC; Wu HJ; Sahin AA; Allison JP; Yu D; Hortobagyi GN; Hung MC
    Nat Commun; 2016 Aug; 7():12632. PubMed ID: 27572267
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cyclin D-CDK4 kinase destabilizes PD-L1 via cullin 3-SPOP to control cancer immune surveillance.
    Zhang J; Bu X; Wang H; Zhu Y; Geng Y; Nihira NT; Tan Y; Ci Y; Wu F; Dai X; Guo J; Huang YH; Fan C; Ren S; Sun Y; Freeman GJ; Sicinski P; Wei W
    Nature; 2018 Jan; 553(7686):91-95. PubMed ID: 29160310
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FAT4 overexpression promotes antitumor immunity by regulating the β-catenin/STT3/PD-L1 axis in cervical cancer.
    Wang D; Wu S; He J; Sun L; Zhu H; Zhang Y; Liu S; Duan X; Wang Y; Xu T
    J Exp Clin Cancer Res; 2023 Sep; 42(1):222. PubMed ID: 37658376
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activation of the PD-1/PD-L1 immune checkpoint confers tumor cell chemoresistance associated with increased metastasis.
    Black M; Barsoum IB; Truesdell P; Cotechini T; Macdonald-Goodfellow SK; Petroff M; Siemens DR; Koti M; Craig AW; Graham CH
    Oncotarget; 2016 Mar; 7(9):10557-67. PubMed ID: 26859684
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression.
    Jiao S; Xia W; Yamaguchi H; Wei Y; Chen MK; Hsu JM; Hsu JL; Yu WH; Du Y; Lee HH; Li CW; Chou CK; Lim SO; Chang SS; Litton J; Arun B; Hortobagyi GN; Hung MC
    Clin Cancer Res; 2017 Jul; 23(14):3711-3720. PubMed ID: 28167507
    [No Abstract]   [Full Text] [Related]  

  • 6. Transforming growth factor beta orchestrates PD-L1 enrichment in tumor-derived exosomes and mediates CD8 T-cell dysfunction regulating early phosphorylation of TCR signalome in breast cancer.
    Chatterjee S; Chatterjee A; Jana S; Dey S; Roy H; Das MK; Alam J; Adhikary A; Chowdhury A; Biswas A; Manna D; Bhattacharyya A
    Carcinogenesis; 2021 Feb; 42(1):38-47. PubMed ID: 32832992
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Saccharide analog, 2-deoxy-d-glucose enhances 4-1BB-mediated antitumor immunity via PD-L1 deglycosylation.
    Kim B; Sun R; Oh W; Kim AMJ; Schwarz JR; Lim SO
    Mol Carcinog; 2020 Jul; 59(7):691-700. PubMed ID: 32115801
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blockage of immune checkpoint molecules increases T-cell priming potential of dendritic cell vaccine.
    Hassannia H; Ghasemi Chaleshtari M; Atyabi F; Nosouhian M; Masjedi A; Hojjat-Farsangi M; Namdar A; Azizi G; Mohammadi H; Ghalamfarsa G; Sabz G; Hasanzadeh S; Yousefi M; Jadidi-Niaragh F
    Immunology; 2020 Jan; 159(1):75-87. PubMed ID: 31587253
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Posttranslational Modifications of PD-L1 and Their Applications in Cancer Therapy.
    Hsu JM; Li CW; Lai YJ; Hung MC
    Cancer Res; 2018 Nov; 78(22):6349-6353. PubMed ID: 30442814
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Juxtacrine Signaling Inhibits Antitumor Immunity by Upregulating PD-L1 Expression.
    Yang WH; Cha JH; Xia W; Lee HH; Chan LC; Wang YN; Hsu JL; Ren G; Hung MC
    Cancer Res; 2018 Jul; 78(14):3761-3768. PubMed ID: 29789418
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Osimertinib (AZD9291) decreases programmed death ligand-1 in EGFR-mutated non-small cell lung cancer cells.
    Jiang XM; Xu YL; Huang MY; Zhang LL; Su MX; Chen X; Lu JJ
    Acta Pharmacol Sin; 2017 Nov; 38(11):1512-1520. PubMed ID: 28880013
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting Glycosylated PD-1 Induces Potent Antitumor Immunity.
    Sun L; Li CW; Chung EM; Yang R; Kim YS; Park AH; Lai YJ; Yang Y; Wang YH; Liu J; Qiu Y; Khoo KH; Yao J; Hsu JL; Cha JH; Chan LC; Hsu JM; Lee HH; Yoo SS; Hung MC
    Cancer Res; 2020 Jun; 80(11):2298-2310. PubMed ID: 32156778
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An increase in BAG-1 by PD-L1 confers resistance to tyrosine kinase inhibitor in non-small cell lung cancer via persistent activation of ERK signalling.
    Lin PL; Wu TC; Wu DW; Wang L; Chen CY; Lee H
    Eur J Cancer; 2017 Nov; 85():95-105. PubMed ID: 28892778
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response.
    Chen G; Huang AC; Zhang W; Zhang G; Wu M; Xu W; Yu Z; Yang J; Wang B; Sun H; Xia H; Man Q; Zhong W; Antelo LF; Wu B; Xiong X; Liu X; Guan L; Li T; Liu S; Yang R; Lu Y; Dong L; McGettigan S; Somasundaram R; Radhakrishnan R; Mills G; Lu Y; Kim J; Chen YH; Dong H; Zhao Y; Karakousis GC; Mitchell TC; Schuchter LM; Herlyn M; Wherry EJ; Xu X; Guo W
    Nature; 2018 Aug; 560(7718):382-386. PubMed ID: 30089911
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Cell-Autonomous Pro-Metastatic Activities of PD-L1 in Breast Cancer Are Regulated by N-Linked Glycosylation-Dependent Activation of STAT3 and STAT1.
    Erlichman N; Meshel T; Baram T; Abu Raiya A; Horvitz T; Ben-Yaakov H; Ben-Baruch A
    Cells; 2023 Sep; 12(19):. PubMed ID: 37830552
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Small Molecule Antagonist of PD-1/PD-L1 Interactions Acts as an Immune Checkpoint Inhibitor for NSCLC and Melanoma Immunotherapy.
    Wang Y; Gu T; Tian X; Li W; Zhao R; Yang W; Gao Q; Li T; Shim JH; Zhang C; Liu K; Lee MH
    Front Immunol; 2021; 12():654463. PubMed ID: 34054817
    [TBL] [Abstract][Full Text] [Related]  

  • 17. N-glycosylation and ubiquitinylation of PD-L1 do not restrict interaction with BMS-202: A molecular modeling study.
    Bailly C; Vergoten G
    Comput Biol Chem; 2020 Oct; 88():107362. PubMed ID: 32871472
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Resveratrol targets PD-L1 glycosylation and dimerization to enhance antitumor T-cell immunity.
    Verdura S; Cuyàs E; Cortada E; Brunet J; Lopez-Bonet E; Martin-Castillo B; Bosch-Barrera J; Encinar JA; Menendez JA
    Aging (Albany NY); 2020 Jan; 12(1):8-34. PubMed ID: 31901900
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PD-L2 glycosylation promotes immune evasion and predicts anti-EGFR efficacy.
    Xu Y; Gao Z; Hu R; Wang Y; Wang Y; Su Z; Zhang X; Yang J; Mei M; Ren Y; Li M; Zhou X
    J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34697216
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of mTOR complex 1/p70 S6 kinase signaling elevates PD-L1 levels in human cancer cells through enhancing protein stabilization accompanied with enhanced β-TrCP degradation.
    Deng L; Qian G; Zhang S; Zheng H; Fan S; Lesinski GB; Owonikoko TK; Ramalingam SS; Sun SY
    Oncogene; 2019 Aug; 38(35):6270-6282. PubMed ID: 31316145
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 60.